IPOs and biotech large caps are poised to ensure a strong finish to the year, in the BioCentury Q4 2014 Financial Markets Preview and Third Quarter Stock Roundup.
Get a comprehensive review of life sciences market performance in Q3 2014, examining fundraising efforts and stock performance both industry-wide and by individual company, in the BioCentury Q4 2014 Financial Markets Preview and Third Quarter Stock Roundup. This report also predicts Q4 market performance in light of factors like an expected pickup in IPOs and biotech large caps continuing to be a major driver.
- Healthcare and biotech fund flows, and follow-on performance
- IPO performance, and IPO queue with status
- Selected products with Phase III or regulatory milestones expected in Q4 2014
- Third-quarter earnings, funds raised, BioCentury 100 indice highlights, price and trading leaders and performance of 717 stocks